MGH/Harvard is recruiting adult males with Fragile X syndrome, 18 years or older, for a neuroimaging study. Participants will be compensated up to $350.
The aim of the study is to examine problems with a chemical messenger called glutamate in the brain in Fragile X syndrome, and how it impacts sensory, motor and cognitive abilities and implicated structural and functional connectivity.
Three visits at Massachusetts General Hospital are required:
- Medical history and behavioral testing (approx. 1.5 hours)
- PET-MRI (approx. 2 hours)
- Magnetoencephalography (approx. 1 hour).
The study started on March 15, 2018, and ends by June 30, 2020. The IRB approval number is 2017P001039.
Travel/time subsidy: compensation up to $350 for participation.
If you are interested, please contact:
Maria Mody, PhD